Chinese equity markets staged a dramatic intraday recovery on Friday, led by the tech-heavy ChiNext index which erased a steep 2% early morning decline to finish in positive territory. This resilience highlights a shifting sentiment among domestic investors who are increasingly decoupling from global volatility to focus on Beijing’s prioritized industrial sectors. Despite a slight cooling in overall trading volume, the market's ability to absorb early selling pressure suggests a robust underlying demand for high-growth tech assets.
The robotics sector emerged as the day's primary catalyst, with more than a dozen companies hitting the daily upward price limit. Firms such as Greatoo Intelligent and Leadshine witnessed a collective surge, fueled by an intensifying race to integrate artificial intelligence with physical manufacturing systems. This 'robotics wave' is not merely speculative; it reflects a strategic pivot toward high-end equipment as China seeks to offset demographic shifts through advanced automation.
Semiconductor equipment manufacturers also continued their upward trajectory, with industry leader Naura Technology seeing its market capitalization momentarily breach the 450-billion-yuan mark. This growth underscores the relative insulation of the 'hard tech' sector from broader macroeconomic concerns. While traditional cyclical sectors like non-ferrous metals experienced a pull-back, the rotation into semiconductors and fluorochemicals suggests that capital is actively seeking refuge in supply-chain-critical industries.
Institutional analysts maintain that technology remains the dominant market narrative for the foreseeable future. With the ChiNext index maintaining levels around the 4,000-point threshold, the focus has shifted toward 'rotation rhythm' and the identification of core assets that can withstand global liquidity shifts. As external markets in Europe and the U.S. face renewed inflationary warnings and bubble concerns, the Chinese market is increasingly leaning on its own policy-driven industrial cycle.